Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Cash from Financing Activities (2021 - 2024)

Historic Cash from Financing Activities for Biofrontera (BFRI) over the last 4 years, with Q4 2024 value amounting to $4.0 million.

  • Biofrontera's Cash from Financing Activities fell 3967.83% to $4.0 million in Q4 2024 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 4836.28%. This contributed to the annual value of $14.8 million for FY2024, which is 7637.62% up from last year.
  • Latest data reveals that Biofrontera reported Cash from Financing Activities of $4.0 million as of Q4 2024, which was down 3967.83% from -$298000.0 recorded in Q3 2024.
  • In the past 5 years, Biofrontera's Cash from Financing Activities registered a high of $43.8 million during Q4 2021, and its lowest value of -$298000.0 during Q3 2024.
  • Over the past 4 years, Biofrontera's median Cash from Financing Activities value was $4.6 million (recorded in 2022), while the average stood at $7.8 million.
  • In the last 5 years, Biofrontera's Cash from Financing Activities soared by 392644.63% in 2022 and then crashed by 15042.3% in 2024.
  • Quarter analysis of 4 years shows Biofrontera's Cash from Financing Activities stood at $43.8 million in 2021, then plummeted by 89.44% to $4.6 million in 2022, then soared by 45.01% to $6.7 million in 2023, then crashed by 39.68% to $4.0 million in 2024.
  • Its Cash from Financing Activities stands at $4.0 million for Q4 2024, versus -$298000.0 for Q3 2024 and $5.3 million for Q2 2024.